Genome Editing– tag –
-
Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND
RegMedNet UK Overview Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secu... -
Beam Therapeutics Pursues Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Citing Positive Phase 1/2 Clinical Data
Simply Wall St USA Overview Beam Therapeutics announced updated Phase 1/2 clinical trial data for BEAM-302, its treatment for Alpha-1 Antitrypsin Deficiency (AATD), showing an acceptable safety profile and promising biomarker data indica... -
CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 2026
MarketBeat USA Overview CRISPR Therapeutics expresses strong optimism for the continued market adoption of its approved gene-editing therapy, CASGEVY, and anticipates significant data updates from multiple key pipeline programs by the en... -
CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval
The Motley Fool USA Overview CRISPR Therapeutics reportedly aims for significant growth over the next decade by building on the commercialization of its approved sickle cell disease and transfusion-dependent beta-thalassemia therapy, CAS... -
Beam Therapeutics’ Base Editing Therapy BEAM-302 Shows Rapid, Sustained AAT Increase in Phase 1/2 for Alpha-1 Antitrypsin Deficiency, Targets Accelerated Approval
GlobeNewswire / Beam Therapeutics Press Releases USA Overview Beam Therapeutics presented updated Phase 1/2 clinical data for its base editing therapy, BEAM-302, for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Socie... -
CRISPR Therapeutics to Detail Pipeline Progress at Morgan Stanley Global Healthcare Conference
CRISPR Therapeutics Press Releases USA Overview CRISPR Therapeutics announced its management will participate in the Morgan Stanley 24th Global Healthcare Conference on September 10, 2026. This engagement provides a critical platform for... -
The Next Frontier in Hematology: China’s Leadership in CAR-T and CRISPR Gene Editing
Source unknown China Overview China has rapidly emerged as a global leader in hematology, achieving significant breakthroughs in CAR-T cell therapy and CRISPR-based hematopoietic stem cell editing. This rapid ascent is profoundly reshapi... -
Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge
Current Opinion in Hematology USA Overview The quest to cure sickle cell disease (SCD) hinges on establishing durable, healthy hematopoiesis without significant toxicity. While cutting-edge in vivo and prenatal hematopoietic stem cell (H... -
CRISPR Gene Editing: Engineering Durable Cures for Congenital Diseases through Stem Cell and Liver Targeting
Liv Hospital Turkey Overview CRISPR gene editing technology promises a revolutionary approach to fundamentally cure congenital diseases by precisely correcting underlying genetic errors. By targeting the liver and hematopoietic stem cell... -
Single-Dose CRISPR Therapy Slashes LDL Cholesterol by 52.5%, Triglycerides by 47.8% in Landmark Phase 1 Trial
Medical Xpress USA Overview Vertex Pharmaceuticals' VERVE-101, a one-time CRISPR-Cas9 gene editing therapy, has achieved significant results in a Phase 1 trial, safely reducing LDL cholesterol by 52.5% and triglycerides by 47.8% in patie...
